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Abstract
Background
The co-occurrence of the c.709-1G>A GRN mutation and the p.A152T MAPT variant has
been identified in 18 Basque families affected by frontotemporal dementia (FTD). We aimed
to investigate the influence of the p.A152T MAPT variant on the clinical and neuropathologi-
cal features of these Basque GRN families.
Methods and findings
We compared clinical characteristics of 14 patients who carried the c.709-1G>A GRN muta-
tion (GRN+/A152T-) with 21 patients who carried both the c.709-1G>A GRN mutation and
the p.A152T MAPT variant (GRN+/A152T+). Neuropsychological data (n = 17) and plasma
progranulin levels (n = 23) were compared between groups, and 7 subjects underwent neuro-
pathological studies. We genotyped six short tandem repeat markers in the two largest fami-
lies. By the analysis of linkage disequilibrium decay in the haplotype block we estimated the
time when the first ancestor to carry both genetic variants emerged.
GRN+/A152T+ and GRN+/A152T- patients shared similar clinical and neuropsychologi-
cal features and plasma progranulin levels. All were diagnosed with an FTD disorder, includ-
ing behavioral variant FTD or non fluent / agrammatic variant primary progressive aphasia,
and shared a similar pattern of neuropsychological deficits, predominantly in executive func-
tion, memory, and language. All seven participants with available brain autopsies (6 GRN
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+/A152T+, 1 GRN+/A152T-) showed frontotemporal lobar degeneration with TDP-43 inclu-
sions (type A classification), which is characteristic of GRN carriers. Additionally, all seven
showed mild to moderate tau inclusion burden: five cases lacked β-amyloid pathology and
two cases had Alzheimer’s pathology. The co-occurrence of both genes within one individ-
ual is recent, with the birth of the first GRN+/A152T+ individual estimated to be within the
last 50 generations (95% probability).
Conclusions
In our sample, the p.A152T MAPT variant does not appear to show a discernible influence
on the clinical phenotype of GRN carriers. Whether p.A152T confers a greater than
expected propensity for tau pathology in these GRN carriers remains an open question.
Introduction
In 2008, our group described a cluster of families with frontotemporal dementia (FTD) har-
boring the c.709-1G>A mutation in the progranulin gene (GRN), a mutation unique to indi-
viduals in the Basque country [1]. The most common presenting clinical syndromes of these
Basque GRN carriers include behavioral variant FTD (bvFTD), followed by nonfluent variant
primary progressive aphasia (nfvPPA), with about half of these patients developing features of
corticobasal syndrome (CBS) throughout their disease course [2]. The clinical phenotype of
the Basque GRN carriers is variable even within families, as has been reported for other GRN
mutations [3–5]. More recently, we found that 71% of these Basque GRN carriers also carry a
rare variant in the microtubule-associated protein tau gene (MAPT) in exon 7 (p.A152T) [6],
which has been linked to risk for both FTD-spectrum disorders and clinical Alzheimer’s dis-
ease (AD) [7,8]. The frequency of the MAPT p.A152T variant is very low in healthy controls
(0.25–0.71%) but is overrepresented in patients with FTD (0.72–1.42%) and AD (0.56–1.02%)
[6,7]. Although the p.A152T residue lies outside of the microtubule-binding region on tau,
functional studies suggest that the p.A152T variant leads to tauopathy and axonal degeneration
[7,9,10].
The co-occurrence of GRN, a pathogenic frontotemporal lobar degeneration (FTLD) muta-
tion, and p.A152T, a genetic risk factor for FTD and AD, in a well-characterized group of
patients enables us to determine the influence of these genes on disease phenotype. Among
these Basque families, MAPT p.A152T has been found to either completely or partially co-seg-
regate with GRN c.709-1G>A [6], which may be due to the fact that the two genes, GRN and
MAPT, are located only 1.7 Mb from each other on chromosome 17. Overall, MAPT p.A152T
was present in nine of the fifteen families [6]. The aim of this study was to explore and date the
origin of these genes in the Basque families and to compare the clinical and neuropathological
phenotypes of GRN carriers with and without p.A152T.
Methods
Participants
Thirty-five patients who carried the c.709-1G>A GRN mutation were included in the clinical
analysis. Clinical diagnoses were reviewed in a consensus conference with three experienced
neurologists (FM, BI, and ALdM) and a neuropsychologist (MB) using clinical criteria for
bvFTD [11], primary progressive aphasia [12] and CBS [13]. We also assessed age of symptom
GRN and MAPT p.A152T in Basque FTD families
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onset and defined motor onset as the time from symptom onset to the development of motor
symptoms. Motor symptoms included gait impairment, falls, dysequilibrium, weakness or
adventitious movements. Motor signs on neurological examination included rigidity, tremor,
bradykinesia, dysequilibrium, or gait disturbance. For the 21 patients with available structural
MRI, the presence or absence of asymmetry was evaluated based on visual inspection.
To estimate the frequency of both genes in the Basque families, we analyzed DNA of 102
subjects, which included the 35 symptomatic patients mentioned above and 67 asymptomatic
members of these c.709-1G>A GRN families. To analyze the prevalence of the p.A152T variant
in the Basque region, we also screened 507 unrelated healthy controls. Healthy controls were
required to have no known neurological disease or cognitive complaints. Moreover, 57
patients with Parkinson’s disease carrying the R1441 or G2019S mutations in the leucine-rich
repeat kinase 2 gene (LRRK2) and 20 patients with myotonic dystrophy type 1 (Steinert dis-
ease) were screened for p.A152T. This study was approved by the Donostia Hospital Ethics
Committee and written informed consent was obtained from all participants or their
surrogates.
Neuropsychological assessment
Eighteen patients were evaluated with a standardized neuropsychological assessment within
the first year of symptom onset. Overall cognitive status was assessed using the Mini-Mental
State Examination (MMSE) [14]. Verbal episodic memory and design copy were tested using
the Word List and the Constructional Praxis subtests from the Consortium to Establish a Reg-
istry for Alzheimer’s Disease (CERAD) [15]. The battery also included the Trail Making Test
Parts A and B (TMT-A and–B) [16] and the GERMCIDE neuropsychological protocol [17]
that is comprised of digit span forward and backward, semantic (animals) and phonetic verbal
fluency, verbal comprehension and repetition, reasoning and unilateral and bilateral praxis
tests. Twelve patients (6 GRN+/A152T+ and 6 GRN+/A152T- underwent follow up neuropsy-
chological testing an average of 12.3± 0.8 months after the first assessment. Change scores in
MMSE between baseline and follow up were compared between the two groups using a two
sample t-test.
Progranulin levels
We compared available plasma progranulin (PGRN) levels of 23 patients, which included 9
GRN+/A152T+ and 14 GRN+/A152T- carriers. Combining all 23 patients into one group, we
correlated PGRN levels with age of onset and also compared PGRN levels between clinical syn-
dromes. Plasma samples were diluted 1:100 in the dilution buffer provided and levels of PGRN
were measured in a duplicate set using a commercial ELISA assay (Progranulin [human] ELISA
kit, AdipoGen, Inc, South Korea; ref AG-45A-0018YEK-KI01) according to the manufacturer’s
instructions. Recombinant human PGRN provided with the ELISA kit was used as a standard.
Genetic studies
Whole blood DNA was extracted using standard procedures. MAPT SNP rs143624519 geno-
typing was performed with a TaqMan allelic discrimination assay with inventoried probes
(Applied Biosystems) and a LightCycler96 PCR system. Genotyping calls were made using
LightCycler96 SW1.1 software (Roche).
To analyze the haplotypes and estimate the age of the mutation, we decided to base the anal-
ysis on the two largest families, Family 1 and Family 2, for which we had DNA samples from
21 and 26 individuals respectively. To examine the haplotype surrounding GRN mutation
c.709-1G>A and MAPT SNP rs143624519, we typed six short tandem repeat (STR) markers
GRN and MAPT p.A152T in Basque FTD families
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spanning a region of 4.46 Mb on chromosome 17q21. All markers (D17S930, D17S1861,
D17S950, D17S934, D17S920, and D17S1868) were amplified with one fluorescently labeled
primer. PCR fragments were analyzed on an ABI 3100 automated DNA analyzer and alleles
were scored using the GeneMapper software (both from Applied Biosystems).
Haplotypes were resolved with PHASE 2.1 [18,19]. The age of the GRNmutation c.709-
1G>A was estimated from Equation 28 in Walsh et al. [20], which estimates the time to the
most recent common ancestor of two individuals based on their genetic differences. We set a
general STR mutation rate of m = 0.001, together with an estimated recombination rate
between the extreme markers in the haplotype of r = 0.022 (from Kong et al. [21]).
Neuropathological studies
Neuropathological studies were carried out at Donostia University Hospital, using samples
from the Neurological Tissue Bank of the Basque Biobank for Research (OEHUN), according
to standardized protocols. The right half of the brain was sliced fresh and stored frozen at
-80˚C. The left half of the brain was fixed in 10% buffered formaldehyde for 3 to 4 weeks. The
histological assessment was performed in 5-μm-thick sections of formalin-fixed paraffin-
embedded blocks of tissue from areas of the left brain, namely, the frontal, temporal, parietal
and occipital cortex, motor cortex, anterior and posterior cingulate cortices, basal ganglia
(including striatum and globus pallidus), nucleus basalis of Meynert, thalamus, amygdala,
anterior and posterior hippocampus with parahippocampal gyrus, midbrain (with rostral and
caudal substantia nigra), pons with locus coeruleus, medulla oblongata, cerebellar vermis, den-
tate nucleus of the cerebellum, and olfactory bulb.
Sections of each tissue block were stained with hematoxylin and eosin; additionally, Luxol
fast blue counterstained with periodic acid-Schiff (PAS) was used on certain blocks. Auto-
mated immunohistochemistry was performed using primary antibodies on a Ventana Bench-
Mark ULTRA slide staining system (Ventana Medical Systems, Tucson, USA). The Ventana
staining procedure included pretreatment with cell conditioner 1 (pH 8) or 2 (pH 6) and for-
mic acid, depending on the antibody, followed by incubation with the corresponding antibody.
This incubation was followed by treatment with ultraView Universal DAB. The primary anti-
bodies used were: anti-β-amyloid (dilution 1:50, monoclonal, clone 12F4, Covance), anti-PHF
tau (dilution 1/2000, monoclonal, clone AT8, Innogenetics), anti-α-synuclein (dilution 1:4000,
monoclonal, clone LB509, Covance), anti-TDP-43 (dilution 1:1000, monoclonal, clone
2E2-D3, Abnova), anti-ubiquitin (dilution 1:300, polyclonal, Dako), anti-PrP (dilution 1:100,
monoclonal, clone 3F4, Millipore), anti-tau (4-repeat isoform RD4) (dilution 1:80, monoclo-
nal, clone 1E1/A6, Millipore), anti-tau (3-repeat isoform RD3) (dilution 1:300, monoclonal,
clone 8E6/C11, Millipore), neurofilament (pre-diluted, monoclonal, clone 2F11, Roche), and
anti-α B-crystallin (dilution 1:500, polyclonal, ABN185, Millipore).
The semi-quantitative analysis of tau inclusions was performed by a neuropathologist
blinded to the genetic status of the patients according to this scheme: -: no inclusions; +: mild
density (isolated tau inclusions, barely noted at low magnification (x100); ++: moderate den-
sity (moderate tau inclusions, easily visible at low magnification (x100); +++: high density
(abundant tau inclusions).
Statistical analysis
For comparisons between groups, categorical variables were compared with the χ2 test or the
Fisher exact test as appropriate. Continuous variables were compared with a t-test or the
Mann-Whitney U test as appropriate for the data, and with a one-way analysis of variance
(ANOVA) when more than two groups were included in the analysis. The Pearson correlation
GRN and MAPT p.A152T in Basque FTD families
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coefficient was used in order to study the linear association between continuous variables, and
the Shapiro-Wilk test determined normality of variables for each group considered. The
Levene’s test was used to check equality between the variances. Statistical analysis was per-
formed using IBM SPSS Statistics for Windows, Version 17.0.0.
Results
Since our previous study revealed that 71% of c.709-1G>A GRNmutation carriers also carried
the p.A152T variant [6], we screened additional Basque individuals in present study to deter-
mine whether the variant occurs more frequently in the Basque population. This screen
included 507 healthy controls and patients with genetic neurological diseases that have a
higher prevalence in the Basque population, including 20 patients with myotonic dystrophy
type 1 and 57 with Parkinson’s disease related to the LRRK2mutation [22]. We found seven p.
A152T healthy control carriers, reflecting a carrier rate of 1.4%. There was one p.A152T carrier
among 57 LRRK2 carriers and no p.A152T carriers were identified among 20 patients with
myotonic dystrophy type 1. Among the 102 individuals in these GRN families with available
DNA, we found that 37 out of 60 GRNmutation carriers also had the p.A152T variant (61.7%
overall, 60% of affected carriers and 64% of presymptomatic carriers) and 5 out of 42 GRN
negative family members (11.9%) carried the p.A152T variant (GRN-/A152T+, Table 1). At
the time of this study, none of the five GRN-/A152T+ had developed neurodegenerative dis-
ease, cognitive complaints or behavioral changes. Among the five GRN-/A152T+, three were
in their eighties, one was in his fifties and one was in her early forties. Linkage disequilibrium
analysis revealed that GRN and p.A152T (located on chromosome 17) were in partial linkage
disequilibrium (D’ = 0.78; r2 = 0.46).
Origin of the mutation
Short Tandem Repeat (STR) haplotype data were available for 5 GRN+ and 16 GRN- individu-
als in Family 1 and for 12 GRN+ and 14 GRN- individuals in Family 2. Both families carried
the GRN c.709-1G>A mutation in the same haplotype, in alleles 106, 91, 128, 185, A, 98 and
185 at the following loci: D17S930, D17S1861, D17S934, D17S950, rs14362519, D17S920 and
D17S1868, respectively. Note that nucleotide A at rs143624519 corresponds to the T amino
acid substitution at MAPTA152T. This haplotype was not found in a sample of 18 control
chromosomes (which all carried various different haplotypes) nor was it found in the 77 GRN-
chromosomes from the affected families. Hence, these two families share the GRN c.709-
1G>A mutation by common descent and the mutation did not arise in each family as two
independent events. Using Equation 28 from Walsh et al. [20], the mutation was estimated
with 95% probability to have arisen 0 to 49 generations ago.
Table 1. MAPT p.A152T and GRN mutation frequencies in 102 Basque GRN family members.
Symptomatic (n) Asymptomatic (n) Total (n)
GRN+/A152T+ 21 16 37
GRN+/A152T- 14 9 23
GRN-/A152T+ 0 5 5
GRN-/A152T- 0 37 37
Total 35 67 102
GRN+: GRN c.709-1G>A mutation carrier; GRN-: non-carrier of the GRN c.709-1G>A mutation; A152T+: MAPT p.A152T carrier; A152T-: non-carrier of
MAPT p.A152T.
https://doi.org/10.1371/journal.pone.0178093.t001
GRN and MAPT p.A152T in Basque FTD families
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In Family 2, three GRN+/A152T- siblings were identified. However, their STR haplotypes
were consistent with a single recombination event between D17S950 and A152T in the trans-
mission of their GRNmutation from their maternal grandfather to their mother, as can be
reconstructed from other descendants of their maternal grandfather (see supporting informa-
tion for pedigrees).
Clinical phenotype
We compared 21GRN+/A152T+ and 14GRN+/A152T- patients for differences in the following
clinical variables: age of onset, initial clinical diagnosis, time to development of motor symptoms,
the development of a secondary symptom of CBS, and asymmetry on structural MRI. For both
GRN+/A152T+ and GRN+/A152T-, the most common clinical syndrome was bvFTD (48% and
64%), followed by nfvPPA (24% and 14%), while AD and CBS were less common presenting syn-
dromes (Table 2). Patients diagnosed with bvFTD (10 in the GRN+/A152T+ group and 9 in the
GRN+/A152T- group) presented primarily with apathy, decreased spontaneous speech output,
deficits in planning and organizing, memory complaints, neglect of self-care and increased appe-
tite, with no apparent difference between genetic groups. All patients diagnosed with nfvPPA
(5 in the GRN+/A152T+ group and 2 in the GRN+/A152T- group) presented with anomia with
non-fluent, effortful speech of varying degree, with diminished spontaneous speech output, articu-
lation deficits, phonemic paraphasias, echolalia and dysgraphia. Most nfvPPA also featured some
degree of impaired sentence comprehension. Overall, language features in patients with nfvPPA
appeared similar in both genetic groups. Patients diagnosed with AD (3GRN+/A152T+ and 2
GRN+/A152T-) had an amnestic syndrome with prominent short-term memory deficits and no
apparent behavioral or motor symptoms. One GRN+/A152T+ patient with CBS had asymmetric
rigidity and bradykinesia associated with limb apraxia.
Two GRN+/A152T+ and one GRN+/A152T- had syndromes that were not consistent with
the four main syndromes in this cohort. These included two GRN+/A152T+ patients with
dementia affecting multiple cognitive domains. The first patient had memory impairment,
anomia, and ideomotor apraxia without evident behavioral symptoms. The second patient
presented with memory impairment, anomia and comprehension impairment, and depressive
symptoms. Neither of these two patients met bvFTD or nfvPPA criteria. One GRN+/A152T-
patient was diagnosed with clinical Parkinson’s disease (PD) at first presentation because his
first symptoms included left-sided rest tremor, rigidity and bradykinesia, and a gait
Table 2. Comparison of demographic and clinical features between groups.
21 GRN+/A152T+ 14 GRN+/A152T- p
Sex (female %) 71.4% 50% 0.29
Age of onset (years) 61.0 ± 7.1 61.4 ± 9.2 0.62
Initial diagnosis bvFTD (10) bvFTD (9) 0.98
nfvPPA (5) nfvPPA (2)
AD (3) AD (2)
CBS (1) CBS (0)
Dementia NOS (2) PD (1)
Time to onset of motor symptoms (years) 3.1 ± 1.3 3.1 ± 1.7 0.84
% developing CBS throughout the disease course 57.1% 35.7% 0.31
% with asymmetry on structural MRI 54.5% 70% 0.66
AD: Alzheimer’s disease; bvFTD: behavioral variant frontotemporal dementia; CBS: corticobasal syndrome; nfvPPA: nonfluent/agrammatic variant of
primary progressive aphasia. NOS: not otherwise specified.
https://doi.org/10.1371/journal.pone.0178093.t002
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abnormality featuring truncal anteflexion and diminished arm swing. He did not improve on
levodopa. He later developed left ideomotor apraxia, focal reflex myoclonus and cortical sen-
sory loss consistent with a diagnosis of corticobasal syndrome.
Although each patient’s behavior changes were not formally assessed with behavioral scales,
apathy, impulsivity and increased appetite represented the most common behavioral symp-
toms. Agitation, hallucinations, delusions and euphoria emerged infrequently, with each pres-
ent in less than 15% of subjects.
The GRN+/A152T+ group showed a higher percentage of subjects developing CBS over the
course of the disease (57.1% vs. 35.7%) compared to GRN+/A152T-, although the difference
was non-significant. GRN+/A152T+ and GRN+/A152T- showed similar mean age of symptom
onset, about 61 years. Time from symptom onset to the development of motor symptoms was
also similar in the two groups. The majority of patients had asymmetrical atrophy on visual
inspection, and there were no significant differences in brain asymmetry between groups.
Neuropsychological phenotype
We compared neuropsychological performance of 8 GRN+/A152T+ with 9 GRN+/A152T-
and found no significant differences between groups for any individual tests. Overall, both
groups showed impairments in executive function, memory, and language. The GRN+/A152T
+ patients had lower scores in measures of executive function, including trail making A and B
and semantic and phonemic verbal fluency, and working memory (digits backward), although
the results did not reach statistical significance. Both groups also showed similar performance
on tests of attention (digit span forward), memory (verbal episodic memory with the Word
List from the CERAD) and praxis. When comparing changes in the MMSE score for 6 GRN
+/A152T+ vs. 6 GRN+/A152T-, we found that the GRN+/A152T+ group had a non-significant
trend for greater decline in MMSE score over 1 year (Table 3).
Table 3. Comparison of neuropsychological performance between groups.
8 GRN+/A152T+ 9 GRN+/A152T- p
MMSE 23.6 ± 4.4 24.5 ± 3.9 0.66
Digit span forward 4.7 ± 0.7 4.6 ± 0.7 0.66
Digit span backward 2.4 ± 1.3 3.1 ± 0.7 0.15
TMT-A 100.8 ± 50.6 76.8 ± 26.3 0.34
TMT-B 200 ± 36.7 180.2 ± 73.9 0.60
Semantic verbal fluency 9.9 ± 4.0 11.3 ± 4.5 0.50
Phonetic verbal fluency 3.7 ± 3.1 7.3 ± 6.2 0.23
Reasoning 5.1 ± 3.5 4.3 ± 2.1 0.54
Verbal comprehension 5.6 ± 0.7 5.9 ± 0.3 0.35
Repetition 9.9 ± 0.3 9.9 ± 0.3 0.93
Unilateral praxis 8.6 ± 3.2 9.8 ± 0.4 0.34
Bilateral praxis 6.1 ± 2.3 6.4 ± 1.7 0.75
CERAD Word List 1 2.2 ± 1.4 2.7 ± 0.9 0.43
CERAD Word List 2 3.6 ± 1.5 4.1 ± 1.1 0.45
CERAD Word List 3 4.7 ± 2.0 5.2 ± 2.1 0.65
CERAD Word List Recall 3.2 ± 1.5 2.4± 2.0 0.34
CERAD Word List Recognition 17.5 ± 1.9 16.3 ± 3.6 0.38
CERAD Constructional Praxis 9.1 ± 3.2 9.3 ± 1.8 0.89
MMSE score change at 1 year -5.2 ± 3.8 -3.7 ± 2.8 0.45
CERAD: Consortium to Establish a Registry for Alzheimer’s Disease; MMSE: Mini-Mental State Examination; TMT: Trail Making Test.
https://doi.org/10.1371/journal.pone.0178093.t003
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Progranulin levels
GRN+/A152T+ showed lower mean progranulin levels (mean: 54 ± 19.1 ng/ml) compared
with those carrying only the GRN mutation (mean: 72.5 ± 31.4 ng/ml), although these results
did not reach statistical significance (Mann-Whitney’s U test: p = 0.201). Interestingly, consid-
ering the distribution of serum PGRN levels, we observed that 5 out of 14 patients (35.7%) in
the GRN+/A152T+ had levels of PGRN below 45 ng/ml and 11 out of 14 (78.6%) below 70 ng/
ml, while these percentages were 0% and 55.5% respectively in the group carrying only the
GRNmutation. Across all patients, PGRN levels did not significantly correlate with the age of
onset (Pearson correlation coefficient, r = -0.260, p = 0.268). There were no differences in
PGRN levels when patients with different clinical syndromes (bvFTD, PNFA, AD, dementia
not otherwise specified and PD) were compared (ANOVA, F = 0.145, p = 0.706). Because of
small sample sizes, we did not perform subgroup analyses comparing the relationship of
PGRN levels versus age of onset between GRN+/A152T+ and GRN+/A152T- or plasma PGRN
stratified by clinical and genetic subtype.
Neuropathological studies
We performed neuropathological assessment in seven patients, including six GRN+/A152T
+ and one GRN+/A152T-. All seven showed histopathological features of FTLD with TAR
DNA-binding protein 43 (TDP-43)-positive inclusions (FTLD-TDP) type A (Fig 1), which is
characteristic of GRNmutation carriers [23,24]. Two of the patients who carried both the GRN
mutation and p.A152T also had Alzheimer’s disease co-pathology. One patient showed a low
density of neuropil threads and pretangles in transentorhinal cortex, β-amyloid deposits in
hippocampus, amygdala, nucleus basalis of Meynert, striatum, insular and cingulate cortex
and neocortex. β-amyloid pathology was absent in midbrain and cerebellum. There were iso-
lated neuritic plaques in neocortex. These findings correspond to a diagnosis of AD neuro-
pathologic change: A2B1C1, according to the National Institute on Aging-Alzheimer’s
Fig 1. Frontotemporal lobar degeneration with TDP-43 type A from a GRN+/A152T+ patient. Numerous
neuronal cytoplasmic inclusions and dystrophic neurites with occasional neuronal intranuclear inclusions in
the superficial cortex.
https://doi.org/10.1371/journal.pone.0178093.g001
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Association (NIA-AA) guidelines for the neuropathologic assessment of AD [25]. The second
patient with AD co-pathology showed a high density of neuropil threads and neurofibrillary
tangles in entorhinal and transentorhinal cortices, and a moderate density of neurofibrillary
tangles in hippocampus and middle temporal gyrus. β-amyloid deposits were present in neo-
cortex, hippocampus, amygdala, nucleus basalis of Meynert, cingulate cortex, neocortex, sub-
stantia nigra and cerebellum. There were also β-amyloid deposits in meningeal vessels.
Isolated neuritic plaques were present in temporal neocortex. These findings correspond to a
diagnosis of Alzheimer disease neuropathologic change: A3B2C1, according to the NIA-AA
guidelines [25].
When we found that the p.A152T variant showed a high frequency in these GRN families, a
neuropathologist (MCC), blinded to the individuals’ genetic status, performed a semi-quanti-
tative analysis of tau pathology in these brains. All of the autopsies showed mild to moderate
tau pathology (Table 4). The tau inclusions seen included neuropil threads (NTs), neurofibril-
lary tangles (NFTs), pretangles (PTs) and astrocytic inclusions, with NTs and PTs showing a
higher burden across the cases (Figs 2 and 3). The amygdala, entorhinal and transentorhinal
cortex and nucleus basalis of Meynert consistently showed tau pathology. The striatum was
usually more affected than the globus pallidus, and in the neocortex, the tau pathology was
most prominent in the temporal lobe, followed by the frontal and occipital lobes. In most
cases, except in the two with a diagnosis of Alzheimer’s disease, these tau inclusions were not
accompanied by β-amyloid pathology. One patient from the GRN+/A152T+ group received an
additional diagnosis of unclassifiable tauopathy because in addition to FTLD-TDP A, tau bur-
den was unusually diffuse and severe, with tau immunoreactivity found in astrocytes in a dis-
tribution that did not clearly fit a defined tauopathy. We found abundant tau-positive deposits
in the cortex in neuronal cytoplasm and threads and grains in the neuropil. There were some
coiled bodies and astrocytic deposits. These inclusions were more abundant in temporal neo-
cortex than in frontal and parietal cortex. In the striatum, there were moderate tau immunore-
active deposits in neuronal cytoplasm and neuropil. In the hippocampus, we found neuronal
cytoplasmic inclusions in the dentate gyrus and CA1, C2, C3 and C4 neurons, but also some
threads, grains, and coiled bodies in the white matter. Abundant tau positive inclusions were
seen in the entorhinal and transentorhinal cortex. We found also tau positive inclusions in the
subthalamic nucleus, substantia nigra and locus coeruleus. There were no tufted astrocytes,
astrocytic plaques or Pick bodies. Immunohistochemistry to determine tau isoforms was per-
formed with a positive control in every slide and revealed a mixed 3R and 4R tauopathy. We
found immunoreactive 3R/4R inclusions in the nucleus basalis of Meynert (neurofibrillary
tangles, isolated granular deposits), amygdala (sparse cytoplasmic neuronal inclusions), and
anterior hippocampus (granular immunoreactive deposits in neuronal cytoplasm). Isolated 4R
isoform was also present in amygdala (neuropil), substantia nigra, anterior hippocampus
(grains in the neuropil) and in oligodendroglia. The immunohistochemistry for tau isoforms
in the neocortex was inconclusive (Fig 3).
Discussion
Here, we describe the clinical and pathological features of a cluster of families that share the
private c.709-1G>A GRNmutation for FTLD and the p.A152T MAPT variant, which has been
identified as a risk factor for AD and FTD-spectrum disorders. Across these 18 Basque fami-
lies, we have identified 37 individuals with both genes, 23 who carry only the c.709-1G>A
GRNmutation, and five who carry only the p.A152T MAPT variant. Those carrying only the
MAPT variant have not developed clinical symptoms. In the families for which we have STR
genotypes, it is clear that the c.709-1G>A GRNmutation resulted from a single event, in a
GRN and MAPT p.A152T in Basque FTD families
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haplotype background carrying p.A152T. For some individuals, the p.A152T MAPT variant
has been lost due to recombination. The c.709-1G>A GRNmutation is estimated to have
arisen within the last 50 generations, that is, roughly 13 centuries.
The partial co-segregation of an FTLD mutation and a genetic risk variant for FTD in this
cohort enabled us to compare the clinical features of GRN+/A152T+ individuals with those
exclusively carrying the GRN mutation. Both groups shared similar clinical and neuropsycho-
logical profiles. The GRN+/A152T+ group showed a trend towards poorer performance in
frontal-executive tests and more decline in their MMSE scores at 1 year, but these findings did
not reach statistical significance. These results suggest that the p.A152T variant has a limited
influence on clinical phenotype in symptomatic c.709-1G>A GRN carriers. Serum progranu-
lin levels were not significantly different in the two groups, though GRN+/A152T+ tended to
have lower progranulin levels.
In contrast, the analysis of brain autopsies suggests that the MAPT variant may possibly
influence neuropathology. As expected, all autopsy cases showed the FTLD-TDP type A
pathology characteristic of GRNmutation carriers. Interestingly, variable degrees of tau
pathology also emerged: one patient had unusually high tau burden and was designated with
an additional diagnosis of an unclassifiable tauopathy, while two patients showed tau pathol-
ogy accompanied by amyloid deposition and thus received a pathologic diagnosis of Alzhei-
mer’s disease. Previous neuropathological analysis of autopsies of individual patients carrying
the p.A152T MAPT variant have shown different types of abnormal tau accumulation: NFTs,
NTs, tufted astrocytes, and oligodendroglial coiled bodies, in different combinations and dis-
tributions. Some fulfilled criteria for corticobasal degeneration, progressive supranuclear palsy
[26], or pallidonigroluysian atrophy [27], while others were considered to have unclassifiable
tauopathies [28]. A few studies have systematically analyzed the co-emergence of FTLD tau
Fig 2. Tau immunohistochemistry from a GRN+/A152T+ patient. (A) Mild immunoreactivity in the
neuronal cytoplasm and threads in the cerebral cortex, x200. (B) Isolated immunoreactivity in the neuronal
cytoplasm and processes in the basal ganglia, x200. (C) Mild immunoreactivity in the cytoplasm and
processes in the amygdala, x200. (D) Mild immunoreactivity in neuronal processes and lack of
immunoreactivity in neuronal cytoplasm in the dentate gyrus of the hippocampus, x200.
https://doi.org/10.1371/journal.pone.0178093.g002
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and TDP-43 pathology. Specifically, tau pathology is generally scant and restricted to the hip-
pocampus and/or entorhinal cortex in most patients with FTLD-TDP [29]. Moreover, previ-
ous studies suggest that GRN brains show reduced tau protein expression, and individuals
with FTLD associated with GRNmutations have a lower propensity for tau pathology than do
other FTLD types, such as FTLD associated with C9ORF72mutations or sporadic FTLD-TDP
[29,30,31]. Thus, the fact that half of our GRN+/A152T+ cases showed significant tau pathol-
ogy, which appears atypical for GRN mutation carriers, may reflect an influence of the p.
A152T MAPT variant.
We have analyzed the influence of a rare genetic MAPT variant on the clinical phenotype of
GRN carriers. Additional genetic risk factors are not usually assessed in the clinical setting
once the disease is explained by a single mutation. However, genetic variants may account for
the clinical heterogeneity in these apparently monogenic mendelian diseases, such as autoso-
mal dominant-FTLD caused by GRN, C9ORF72 or MAPTmutations. In this context, reports
of “double mutations” in FTLD-related genes [32–37] outline the likely influence of more than
one gene on disease pathogenesis and phenotype, supporting an oligogenic, rather than mono-
genic disease model.
Limitations of this study include its relatively small sample size, which poses a challenge for
determining the pathogenic nature of the p.A152T MAPT variant in our study population and
clinical data obtain by retrospective chart review. Second, our results may be unique to families
of Basque descent due to their specific genetic background. Nevertheless, we anticipate that
future in-depth genetic analyses of families carrying pathogenic mutations will shed light on
potential genetic modifiers and disease mechanisms in these complex, heterogeneous neurode-
generative diseases.
Fig 3. Tau immunohistochemistry from a GRN+/A152T+ patient diagnosed with unclassifiable
tauopathy. (A) Strong diffuse neuronal cytoplasm immunoreactivity and threads in the cerebral cortex, x200.
(B) Mild immunoreactivity in the neuronal cytoplasm and processes in the basal ganglia, x200. (C) Moderate
diffuse neuronal cytoplasm immunoreactivity, some neurofibrillary tangles and grains in the neuronal
processes in the amygdala, x200. (D) Moderate diffuse neuronal cytoplasm immunoreactivity in the neuronal
cytoplasm of the dentate gyrus and threads in the hippocampus, x200.
https://doi.org/10.1371/journal.pone.0178093.g003
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Supporting information
S1 Fig. Family 1 pedigree. The symbol  represents subjects that contributed to the haplotype
analysis.
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S2 Fig. Family 2 pedigree. The symbol  represents subjects that contributed to the haplotype
analysis. The symbol + represents the three GRN+/A152T- subjects from this family cited in
the text.
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